12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ADX71149: Phase IIa data

Addex reported top-line data from the double-blind, placebo-controlled Part B portion of a European Phase IIa trial in 92 patients receiving stable doses of antipsychotics showing that twice-daily 50 and 150 mg ADX71149 "met the primary objectives of safety and tolerability." Additionally, the twice-daily 50 mg dose was identified as having...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >